<PAGE>

------------------------------------------------------------------------------
------------------------------------------------------------------------------

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                -----------------

                                    FORM 10-Q

                QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                  For the quarterly period ended April 30, 1999

                         Commission File Number 0-26670

                                -----------------

                         NORTH AMERICAN SCIENTIFIC, INC.
             (Exact name of registrant as specified in its charter)


          Delaware                                             51-0366422
(State or other jurisdiction of                             (I.R.S. Employer
incorporation or organization)                           Identification No.)


                   20200 Sunburst Street, Chatsworth, CA 91311
                    (Address of principal executive offices)


                                 (818) 734-8600
              (Registrant's telephone number, including area code)

                                -----------------



     Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
                                                                [X] Yes [ ] No



     The number of shares of Registrant's Common Stock, $.01 par value,
outstanding as of May 18, 1999 was 6,804,137 shares.

------------------------------------------------------------------------------
------------------------------------------------------------------------------


<PAGE>

                         NORTH AMERICAN SCIENTIFIC, INC.

                                      INDEX

<TABLE>
<CAPTION>
                                                                                         PAGE
                                                                                         ----
                         PART I - FINANCIAL INFORMATION

<S>                                                                                      <C>
ITEM 1.       FINANCIAL STATEMENTS

     Consolidated Balance Sheets as of April 30, 1999 and October 31, 1998...............   3

     Consolidated Statements of Income for the three months and six months
        ended April 30, 1999 and 1998 ...................................................   4

     Consolidated Statements of Cash Flows for the six months
       ended April 30, 1999 and 1998 ....................................................   5

     Condensed Notes to Consolidated Financial Statements ...............................   6



ITEM 2.       MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
              RESULTS OF OPERATIONS .....................................................   8




                           PART II - OTHER INFORMATION


ITEM 4.       SUBMISSIONS OF MATTERS TO A VOTE OF SECURITY HOLDERS.......................   12

ITEM 6.       EXHIBITS AND REPORTS ON FORM 8-K

     Exhibits ...........................................................................   12

     Reports on Form 8-K ................................................................   12
</TABLE>




<PAGE>

                         NORTH AMERICAN SCIENTIFIC, INC.

                           CONSOLIDATED BALANCE SHEETS


<TABLE>
<CAPTION>
                                                                                      APRIL 30,       OCTOBER 31,
                                                                                        1999             1998
                                                                                     -----------    -------------
                                                                                     (UNAUDITED)
<S>                                                                                  <C>            <C>
ASSETS

Current assets
   Cash and cash equivalents .....................................................   $  1,456,000   $  2,119,000
   Marketable securities .........................................................      8,100,000      9,101,000
   Accounts receivable, net ......................................................      1,346,000      1,323,000
   Inventories ...................................................................        658,000        731,000
   Prepaid expenses and other current assets......................................        262,000        196,000
                                                                                     ------------   ------------

     Total current assets ........................................................     11,822,000     13,470,000

Notes receivable..................................................................      2,373,000      1,163,000
Equipment and leasehold improvements, net ........................................      3,153,000      1,587,000
Advances on construction of equipment ............................................      2,744,000      2,289,000 
Deposits and other assets ........................................................        481,000        394,000
                                                                                     ------------   ------------

       Total assets ..............................................................   $ 20,573,000   $ 18,903,000
                                                                                     ------------   ------------
                                                                                     ------------   ------------

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities
   Accounts payable ..............................................................   $    423,000   $    338,000
   Accrued expenses ..............................................................        357,000        202,000
   Income taxes payable ..........................................................        564,000        376,000 
                                                                                     ------------   ------------

     Total current liabilities ...................................................      1,344,000        916,000
                                                                                     ------------   ------------
Stockholders' equity
   Preferred stock, $.01 par value, 2,000,000 shares authorized;
     no shares issued.............................................................             -              - 
   Common stock, $.01 par value, 40,000,000 shares authorized; 6,804,137
     and 6,787,975 shares issued and outstanding as of April 30, 1999 and
     October 31, 1998, respectively...............................................         68,000         68,000
   Additional paid-in capital ....................................................     17,177,000     17,162,000
   Retained earnings .............................................................      1,984,000        757,000
                                                                                     ------------   ------------

     Total stockholders' equity ..................................................     19,229,000     17,987,000
                                                                                     ------------   ------------

     Total liabilities and stockholders' equity ..................................   $ 20,573,000   $ 18,903,000
                                                                                     ------------   ------------
                                                                                     ------------   ------------
</TABLE>

               See notes to the consolidated financial statements.



<PAGE>



                         NORTH AMERICAN SCIENTIFIC, INC.

                        CONSOLIDATED STATEMENTS OF INCOME

<TABLE>
<CAPTION>
                                                                 THREE MONTHS ENDED         SIX MONTHS ENDED
                                                                      APRIL 30,                 APRIL 30,
                                                              ------------------------  ------------------------
                                                                 1999          1998         1999         1998
                                                              ------------------------  ------------------------
                                                                     (UNAUDITED)               (UNAUDITED)
<S>                                                           <C>          <C>          <C>          <C>
Net sales...................................................  $ 3,007,000  $ 1,353,000  $ 5,434,000  $ 2,172,000

Cost of goods sold..........................................    1,095,000      587,000    2,004,000    1,103,000
                                                              -----------  -----------  -----------  -----------

     Gross profit ..........................................    1,912,000      766,000    3,430,000    1,069,000
                                                              -----------  -----------  -----------  -----------

Selling, general and administrative expenses ...............      765,000      453,000    1,463,000      811,000
Research and development....................................      112,000       26,000      204,000       67,000
                                                              -----------  -----------  -----------  -----------

Income from operations .....................................    1,035,000      287,000    1,763,000      191,000

Interest and other income...................................      129,000      143,000      251,000      309,000
                                                              -----------  -----------  -----------  -----------

Income before provision for income taxes ...................    1,164,000      430,000    2,014,000      500,000

Provision for income taxes .................................      447,000      151,000      787,000      179,000
                                                              -----------  -----------  -----------  -----------

Net income .................................................  $   717,000  $   279,000  $ 1,227,000  $   321,000
                                                              -----------  -----------  -----------  -----------
                                                              -----------  -----------  -----------  -----------

Earnings per share

   Basic ...................................................  $       .11  $       .04  $       .18  $       .05
                                                              -----------  -----------  -----------  -----------
                                                              -----------  -----------  -----------  -----------

   Diluted..................................................  $       .10  $       .04  $       .17         $.05
                                                              -----------  -----------  -----------  -----------
                                                              -----------  -----------  -----------  -----------

Weighted average number of common and
 common equivalent shares outstanding

   Basic  ..................................................    6,794,806    6,408,264    6,791,351    6,292,283
                                                              -----------  -----------  -----------  -----------
                                                              -----------  -----------  -----------  -----------

   Diluted .................................................    7,140,065    7,159,203    7,156,634    7,052,716
                                                              -----------  -----------  -----------  -----------
                                                              -----------  -----------  -----------  -----------
</TABLE>


    The accompanying notes are an integral part of the consolidated financial
                                   statements


<PAGE>

                         NORTH AMERICAN SCIENTIFIC, INC.

                      CONSOLIDATED STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>
                                                                                          SIX MONTHS ENDED
                                                                                              APRIL 30,
                                                                                   -----------------------------
                                                                                        1999              1998
                                                                                   -------------    ------------
                                                                                             (UNAUDITED)
<S>                                                                                <C>              <C>
Cash flows from operating activities:
    Net income..................................................................   $   1,227,000    $    321,000
    Adjustments to reconcile net income to net cash
      provided by operating activities
        Depreciation and amortization ..........................................         159,000          85,000
        Changes in assets and liabilities
          Accounts receivable ..................................................         (23,000)       (382,000)
          Inventories ..........................................................          73,000         (75,000)
          Income taxes receivable...............................................               -         106,000 
          Prepaid expenses and other assets ....................................        (168,000)       (266,000)
          Accounts payable .....................................................          85,000         368,000
          Accrued expenses .....................................................         155,000          39,000
          Income taxes payable .................................................         188,000         106,000
                                                                                   -------------    ------------

                  Net cash provided by operating activities.....................       1,696,000         302,000
                                                                                   -------------    ------------

Cash flows from investing activities:
    Advances on construction of equipment.......................................        (455,000)     (1,531,000) 
    Net sales of marketable securities .........................................       1,001,000              - 
    Notes receivable............................................................      (1,210,000)             - 
    Capital expenditures .......................................................      (1,710,000)       (892,000)
                                                                                   -------------    ------------

                  Net cash used in investing activities ........................      (2,374,000)     (2,423,000)
                                                                                   -------------    ------------

Cash flows from financing activities:
    Net proceeds from issuance of common stock..................................          15,000      13,301,000
                                                                                   -------------    ------------

                  Net cash provided by financing activities ....................          15,000      13,301,000
                                                                                   -------------    ------------

Net (decrease) increase in cash and cash equivalents ...........................        (663,000)     11,180,000

Cash and cash equivalents at beginning of period ...............................       2,119,000       1,596,000
                                                                                   -------------    ------------

Cash and cash equivalents at end of period .....................................   $   1,456,000    $ 12,776,000
                                                                                   -------------    ------------
                                                                                   -------------    ------------

Supplemental disclosure of cash flow information:

    Income taxes paid...........................................................   $     598,000    $          -
                                                                                   -------------    ------------
                                                                                   -------------    ------------
</TABLE>

               See notes to the consolidated financial statements.


<PAGE>

                         NORTH AMERICAN SCIENTIFIC, INC.

              CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (UNAUDITED)


NOTE 1 - CONSOLIDATED FINANCIAL STATEMENTS

The consolidated financial information as of April 30, 1999 and for the three
months and six months then ended is unaudited. In the opinion of the Company,
the unaudited financial information is presented on a basis consistent with the
audited financial statements and contains all adjustments, consisting only of
normal recurring adjustments, necessary for a fair statement of the results for
such interim periods. The results of operations for interim periods are not
necessarily indicative of results of operations for the full year. The interim
financial statements should be read in conjunction with the audited financial
statements and notes thereto included in the Company's Annual Report on Form
10-KSB for the fiscal year ended October 31, 1998.


NOTE 2 - MARKETABLE SECURITIES

The Company considers its marketable securities available-for-sale as defined in
Statement of Financial Accounting Standards ("SFAS") No. 115. There were no
material realized or unrealized gains or losses nor any material differences
between estimated fair values, based upon quoted market prices, and the costs of
securities as of April 30, 1999.

NOTE 3 - INVENTORIES

Inventories are stated at the lower of cost or market. Cost is determined in a
manner which approximates the first-in, first-out method. Inventories are shown
net of applicable reserves and allowances. Inventories consist of the following:

<TABLE>
<CAPTION>
                             April 30,         October 31,
                               1999               1998
                               ----               ----
     <S>                     <C>               <C>
     Raw materials           $ 440,000         $ 606,000
     Work in process            66,000            16,000
     Finished goods            152,000           109,000
                             ---------         ---------
                             $ 658,000         $ 731,000
                             ---------         ---------
                             ---------         ---------
</TABLE>

<PAGE>

NOTE 4 - NET INCOME PER SHARE

Basic earnings per share is computed by dividing the net income by the weighted
average number of shares outstanding for the period. Diluted earnings per share
is computed by dividing the net income by the sum of the weighted average number
of common shares outstanding for the period plus the assumed exercise of all
dilutive securities by applying the treasury stock method. The following table
sets forth the computation of basic and diluted earnings per share:

<TABLE>
<CAPTION>
                                                                  THREE MONTHS ENDED                     SIX MONTHS ENDED
                                                                      APRIL 30,                              APRIL 30,
                                                            ------------------------------          ------------------------------
                                                               1999               1998                 1999               1998
                                                            ----------          ----------          ----------         -----------
                                                                     (UNAUDITED)                             (UNAUDITED)
     <S>                                                    <C>                 <C>                 <C>                 <C>
     Net income                                             $  717,000          $  279,000          $1,227,000          $  321,000
                                                            ----------          ----------          ----------          ----------
                                                            ----------          ----------          ----------          ----------
     Weighted average shares outstanding (basic)             6,794,806           6,408,264           6,791,351           6,292,283

     Dilutive effect of stock options and warrants             345,259             750,939             365,283             760,433

     Diluted shares outstanding                              7,140,065           7,159,203           7,156,634           7,052,716
                                                            ----------          ----------          ----------          ----------
                                                            ----------          ----------          ----------          ----------
     Basic earnings per share                               $      .11          $      .04          $      .18          $      .05
                                                            ----------          ----------          ----------          ----------
                                                            ----------          ----------          ----------          ----------
     Diluted earnings per share                             $      .10          $      .04          $      .17          $      .05
                                                            ----------          ----------          ----------          ----------
                                                            ----------          ----------          ----------          ----------
</TABLE>


                                      -7-
<PAGE>

                         NORTH AMERICAN SCIENTIFIC, INC.

ITEM 2.    MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
                            AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with the
Consolidated Financial Statements contained herein and the notes thereto.
Certain matters discussed in this quarterly report on Form 10-Q are forward
looking as that term is defined by: (i) the Private Securities Litigation Reform
Act of 1995 (the "1995 Act") and (ii) releases issued by the SEC. These
statements are being made pursuant to the provisions of the 1995 Act and with
the intention of obtaining the benefits of the "Safe Harbor" provisions of the
1995 Act. The Company cautions investors that any forward looking statements
made by the Company are not guarantees of future performance and that actual
results may differ materially from those in such forward looking statements as a
result of various factors, including, but not limited to any risks detailed
herein or detailed from time to time in the Company's filings with the SEC,
including those factors identified under "Business-Risk Factors" in the
Company's Annual Report on Form 10-KSB for the fiscal year ended October 31,
1998. Any forward-looking statements herein speak only as of the date of this
Form 10-Q, and the Company undertakes no obligation to revise or update any
forward-looking statements, whether as a result of new information, future
results or otherwise.

                              RESULTS OF OPERATIONS

THREE MONTHS ENDED APRIL 30, 1999 COMPARED TO THREE MONTHS ENDED APRIL 30, 1998

NET SALES. Net sales increased $1,654,000, or 122%, to $3,007,000 for the three
months ended April 30, 1999 from $1,353,000 for the three months ended April 30,
1998. The increase in net sales was due primarily to the increase in revenues
generated from the I-125 brachytherapy product line. Sales of the Pd-103
brachytherapy product line which was introduced in April 1999 were not
significant. Sales of the non-therapeutic lines decreased approximately
$125,000.

GROSS PROFIT. Gross profit increased $1,146,000 or 150% to $1,912,000 for the
three months ended April 30, 1999 from $766,000 for the three months ended April
30, 1998. Gross profit as a percent of sales increased from 57% to 64% during
this period. The increase in gross profit as a percentage of sales was primarily
attributable to the significant proportionate increase in revenues from the
I-125 brachytherapy product line in the second quarter of fiscal 1999, which
yield greater gross margins than the Company's non-therapeutic product lines.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES. Selling, general and
administrative ("SG&A") expenses increased $312,000, or 69%, to $765,000 for the
three months ended April 30, 1999 from $453,000 for the three months ended April
30, 1998. SG&A as a percent of net sales decreased to 25% for the three months
ended April 30, 1999 from 33% for the same period in 1998. SG&A expenses
increased primarily due to the following: (i) the Company added a significant
number of administrative personnel throughout fiscal 1998 and continuing into
fiscal 1999 to support the growth of the Company, (ii) the Company leased a new
facility in September 1998 that houses Pd-103 seed production, product
development and corporate offices and (iii) other general and administrative
expenses were increased to give effect to management's plans for the expansion
of the Company.

RESEARCH AND DEVELOPMENT. Research and development efforts continued into the
second quarter of 1999 with such expenditures totaling $112,000 during this
period compared to $26,000 in the corresponding 1998 period. The increase was
due primarily to development efforts associated with new product lines. Such
expenditures may increase in future periods.

INCOME FROM OPERATIONS. Income from operations increased $748,000 to $1,035,000
for the three months ended April 30, 1999, from $287,000 for the three months
ended April 30, 1998. This increase is a result of a combination of the factors
described above.



                                      -8-

<PAGE>

INTEREST AND OTHER INCOME. Interest and other income decreased $14,000 to
$129,000 for the three months ended April 30, 1999 from $143,000 for the three
months ended April 30, 1998. The Company maintained a lower average cash and
investments balance for the quarter ended April 30, 1999 compared to April 30,
1998 as a result of the investment of funds to expand the brachytherapy product
lines and build out the Company's new facility.

NET INCOME. Net income increased $438,000 to $717,000 for the three months ended
April 30, 1999 from $279,000 for the three months ended April 30, 1998. The
increase is a result of the factors described above.


SIX MONTHS ENDED APRIL 30, 1999 COMPARED TO SIX MONTHS ENDED APRIL 30, 1998

NET SALES. Net sales increased $3,262,000, or 150%, to $5,434,000 for the six
months ended April 30, 1999 from $2,172,000 for the six months ended April 30,
1998. The increase in net sales was due primarily to the increase in revenues
generated from the I-125 brachytherapy product line. Sales of the Pd-103
brachytherapy product line which was introduced in April 1999 were not
significant. Sales of the non-therapeutic lines decreased approximately
$130,000.

GROSS PROFIT. Gross profit increased $2,361,000 or 221% to $3,430,000 for the
six months ended April 30, 1999 from $1,069,000 for the six months ended April
30, 1998. Gross profit as a percent of sales increased from 49% to 63% during
this period. The increase in gross profit as a percentage of sales was primarily
attributable to the significant proportionate increase in revenues from the
I-125 brachytherapy product line in the first six months of fiscal 1999, which
yield greater gross margins than the Company's non-therapeutic product lines.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES. Selling, general and
administrative ("SG&A") expenses increased $652,000, or 80%, to $1,463,000 for
the six months ended April 30, 1999 from $811,000 for the six months ended April
30, 1998. SG&A as a percent of net sales decreased to 27% for the six months
ended April 30, 1999 from 37% for the same period in 1998. SG&A expenses
increased primarily due to the following: (i) the Company added a significant
number of administrative personnel throughout fiscal 1998 and continuing into
fiscal 1999 to support the growth of the Company, (ii) the Company leased a new
facility in September 1998 that houses Pd-103 seed production, product
development and corporate offices and (iii) other general and administrative
expenses were increased to give effect to management's plans for the expansion
of the Company.

RESEARCH AND DEVELOPMENT. Research and development efforts continued into the
first half of 1999 with such expenditures totaling $204,000 during this period
compared to $67,000 in the corresponding 1998 period. The increase was due
primarily to development efforts associated with new product lines. Such
expenditures may increase in future periods.

INCOME FROM OPERATIONS. Income from operations increased $1,572,000 to
$1,763,000 for the six months ended April 30, 1999, from $191,000 for the six
months ended April 30, 1998. This increase is a result of a combination of the
factors described above.


                                      -9-

<PAGE>

INTEREST AND OTHER INCOME. Interest and other income decreased $58,000 to
$251,000 for the six months ended April 30, 1999 from $309,000 for the six
months ended April 30, 1998. The Company maintained a lower average cash and
investments balance for the six months ended April 30, 1999 compared to April
30, 1998 as a result of the investment of funds to expand the brachytherapy
product lines and build out the Company's new facilities.

NET INCOME. Net income increased $906,000 to $1,227,000 for the six months ended
April 30, 1999 from $321,000 for the six months ended April 30, 1998. The
increase is a result of the factors described above.


                                      -10-
<PAGE>

                         LIQUIDITY AND CAPITAL RESOURCES

At April 30, 1999, the Company had cash and investments in marketable securities
aggregating approximately $9.6 million and working capital of $10.5 million. For
the six months ended April 30, 1999, net cash provided by operating activities
was approximately $1.6 million. Net cash used in investing activities primarily
for capital expenditures, convertible notes receivable and advances on
construction of equipment totaled approximately $2.3 million during the six
months ended April 30, 1999.

The Company is authorized to purchase up to $1.5 million of the Company's common
stock on the open market. No such shares have been repurchased as of April 30,
1999.

To date, the Company's short term liquidity needs have generally consisted of
operating capital to finance growth in inventories, trade accounts receivable
and new product development as well as to take advantage of strategic
investments in related businesses. The Company has satisfied these needs
primarily through a combination of private equity financings and from cash
generated by operations. The Company has no long-term debt or a current need for
a line of credit or similar arrangement with a bank. Management anticipates that
its existing cash resources will be sufficient to fund its planned expansion
over the next twelve months, although additional funding may be required to fund
the acquisition and/or the development of complementary businesses, technologies
or products.

YEAR 2000 COMPLIANCE. The Year 2000 issue arises from the fact that most
computer software programs have been written using two digits rather than four
to represent a specific year. Any computer programs that have date-sensitive
software may recognize a date using "00" as the year 1900 rather than the year
2000. This could result in a system failure or miscalculation causing disruption
of operations, including among other things, a temporary inability to process
transactions, send invoices or engage in similar normal business activities.

In an effort to address our Year 2000 exposure the Company assembled a team of
senior managers to create a program that included IT and non-IT components
(office productivity, manufacturing, product, computer, and systems). For each
component area, the team has created projects to identify and address the risks
associated with the new millennium and leap year. The projects include:

-    Strategic Customer and Supplier Evaluation;
-    Component Assessment;
-    Non-compliance Resolution;
-    Testing; and
-    Documentation.

Further, the Company has added a Year 2000 assessment and disclosure step to the
purchasing process. Hereafter, each IT and non-IT component acquisition must
include a Year 2000 product assessment.

Based upon this ongoing assessment, the Company believes that it will not be
required to modify or replace significant portions of its component inventory to
address Year 2000 issues.

In addition to risks associated with internal components, the Company has
relationships with, and is to varying degrees dependent upon, third parties that
provide us with information, goods and services. These include financial
institutions, suppliers, vendors, research partners and governmental entities,
as well as customers and distributors. External agent risks remain outside of
our control, however the Company has instituted programs to identify and assess
our external agents' Year 2000 compliance. To date, the Company has received no
indication from any material third party that they anticipate any Year 2000
compliance problems.


                                      -11-

<PAGE>

The Company will continue to assess Year 2000 compliance on an on-going basis,
including monitoring new products and conducting surveys with third parties to
ensure Year 2000 issues are resolved in a timely manner. Additionally, the
Company is developing a contingency plan which it will put into effect in the
event of any currently unanticipated Year 2000 compliance issues.

All aspects of the Company's Year 2000 program are expected to be completed in
mid-1999. Total costs to resolve the Year 2000 issue have not been and are not
expected to be material to the Company's financial position, results of
operations or cash flows.

The foregoing is a Year 2000 readiness disclosure entitled to protection as
provided in the Year 2000 Information and Readiness Disclosure Act.



PART II - OTHER INFORMATION



The Company was not required to report any information pursuant to Items 1
through 6 of Part II of Form 10-Q except as follows:

ITEM 4        SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

On March 19, 1999, the Company held its 1999 Annual Meeting of Stockholders. The
following persons were elected as directors to hold office until the 2000 Annual
Meeting of Stockholders: Irwin J. Gruverman, L. Michael Cutrer, Dr. Allan M.
Green, Larry Berkin and Michael C. Lee. The number of shares cast for, withheld
and abstained with respect to each of the nominees were as follows:

<TABLE>
<CAPTION>
                NOMINEE                    FOR            WITHHELD          ABSTAINED
             <S>                        <C>               <C>               <C>
              Gruverman                 6,550,997          38,579               0
              Cutrer                    6,550,847          38,729               0
              Green                     6,550,847          38,729               0
              Berkin                    6,550,997          38,579               0
              Lee                       6,550,397          39,179               0
</TABLE>

The stockholders also voted to approve the ratification of the selection of
PricewaterhouseCoopers LLP as independent accountants for the Company for the
fiscal year ending October 31, 1999. A total of 6,588,121 shares were cast for
the adoption of the proposal, 30,122 shares were cast against this proposal, and
1,333 shares abstained.


ITEM 6.       EXHIBITS AND REPORTS ON FORM 8-K

a.   Exhibits - The following Exhibits are filed herewith:

     Exhibit 27 - Financial Data Schedule (EDGAR only)

b.   Reports on Form 8-K - No reports on Form 8-K have been filed during the
     quarter for which this report is filed.


                                      -12-

<PAGE>

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.



                              NORTH AMERICAN SCIENTIFIC, INC.




May 20, 1999         By:      /s/ L. Michael Cutrer
                              ------------------------------------------
                              Name:    L. Michael Cutrer
                              Title:   President and
                                       Chief Executive Officer
                                       (Principal Executive Officer)



May 20, 1999         By:      /s/ Alan I. Edrick
                              ------------------------------------------
                              Name:    Alan I. Edrick
                              Title:   Chief Financial Officer
                                       (Principal Financial and 
                                       Accounting Officer)


                                      -13-